Assessment Status | Rapid Review Complete |
HTA ID | 23020 |
Drug | Pegunigalsidase alfa |
Brand | Elfabrio® |
Indication | Pegunigalsidase alfa (Elfabrio®) is indicated for long-term enzyme replacement therapy in adult patients with a confirmed diagnosis of Fabry disease (deficiency of alpha-galactosidase). |
Assessment Process | |
Rapid review commissioned | 19/04/2023 |
Rapid review completed | 24/05/2023 |
Rapid review outcome | A full HTA is not recommended. The NCPE recommends that pegunigalsiadase alfa not be considered for reimbursement at the submitted price*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.